1FX — Ananda Pharma Share Price
Last trade - 00:00- €2.15m
- €2.36m
- £0.00m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.35 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 304.38 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -1548.22% | ||
| Return on Equity | -1049.01% | ||
| Operating Margin | -86710.39% | ||
Financial Summary
| Year End 31st Jan | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | n/a | n/a | n/a | n/a | 0 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Ananda Pharma plc is a United Kingdom-based company focused on the development and commercialization of cannabidiol (CBD)-based therapies. It is engaged in developing medicines for the treatment of drug-resistant epilepsies and specific inflammatory pain conditions (starting with chemotherapy induced peripheral neuropathy (CIPN) & endometriosis) and Heart Failure with preserved Ejection Fraction (HFpEF). ACTiON is a Phase II, double blind placebo-controlled crossover randomized clinical trial (RCT) to assess its MRX1 drug candidate versus placebo in the treatment of CIPN. ENDOCAN-1 shall help determining whether a cannabinoid can reduce endometriosis-associated pain. HFpEF is a study designed to evaluate the cardioprotective effects of its MRX1 drug candidate in a preclinical HFpEF model. Its two novel cannabinoid medicines: MRX2 (CBD) and MRX2T, helps in a range of seizure types and epilepsies in children and adults.
Directors
- Last Annual
- January 31st, 2025
- Last Interim
- July 31st, 2025
- Incorporated
- January 19th, 2018
- Public Since
- July 4th, 2018
- No. of Employees
- 2
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Stuttgart Stock Exchange
- Shares in Issue
- 4,299,146,581
- Address
- C/O Arch Law Limited, LONDON, EC2N 4BQ
- Web
- https://www.anandapharma.co.uk/
- Phone
- Auditors
- PKF Littlejohn LLP
Similar to 1FX
Magforce AG
Stuttgart Stock Exchange
Vidac Pharma Holding
Stuttgart Stock Exchange
FAQ
As of Today at 18:16 UTC, shares in Ananda Pharma are trading at €0.00. This share price information is delayed by 15 minutes.
Shares in Ananda Pharma last closed at €0.00 and the price had moved by -85.71% over the past 365 days. In terms of relative price strength the Ananda Pharma share price has underperformed the FTSE Global All Cap Index by -87.73% over the past year.
There is no consensus recommendation for this security.
Find out moreAnanda Pharma does not currently pay a dividend.
Ananda Pharma does not currently pay a dividend.
Ananda Pharma does not currently pay a dividend.
To buy shares in Ananda Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €0.00, shares in Ananda Pharma had a market capitalisation of €2.15m.
Here are the trading details for Ananda Pharma:
- Country of listing: Germany
- Exchange: STU
- Ticker Symbol: 1FX
Based on an overall assessment of its quality, value and momentum Ananda Pharma is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ananda Pharma. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -77.18%.
As of the last closing price of €0.00, shares in Ananda Pharma were trading -75.31% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Ananda Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Ananda Pharma's directors